Medprin Regenerative Medical Technologies Co. Ltd.

Medprin Regenerative Medical Technologies Co. Ltd.

SSZSE:301033
49.17
CNY
-0.38
(-0.77%)
1.90EPS
28.14P/E
3.63BMarket Cap
Apr 16Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.28
1.89
2.29
2.51
2.72
2.94
3.5
4.24
5.58
6.18
Basic EPS, GAAP
-0.46
-0.41
0.56
0.75
0.79
0.54
0.62
1.2
1.71
1.91
Free Cash Flow per Basic Share
-0.67
-0.32
-0.11
-0.56
-1.52
-1.32
1.03
1.27
1.75
- -
Dividend per Share
- -
- -
- -
- -
- -
0.12
0.23
0.41
0.6
- -
Book Value per Share
2.27
5.48
6.04
6.75
8.66
9.12
9.63
10.52
11.9
12.77
Tangible Book Value per Share
1.67
4.74
5
5.48
7.51
7.87
8.2
9.09
10.4
11.29
Basic Weighted Avg Shares
42
45
49
49
57
66
66
66
66
67
Sales/Revenue/Turnover
54
86
113
124
154
195
231
278
369
414
Operating Margin (%)
-47.1
-25.06
100
28.22
24.37
16.97
19.57
31.24
34.42
35.34
Depreciation Expense
3
4
4
5
8
15
25
27
27
- -
Net Income, GAAP
-19
-19
28
37
45
36
41
79
113
128
Effective Tax Rate (%)
- -
- -
11.21
14.3
13.41
10.58
14.88
15.35
10.34
9.82
Profit Margin (%)
-35.87
-21.68
24.44
29.93
29.08
18.38
17.71
28.32
30.67
30.84
Working Capital
56
198
190
194
363
156
202
265
324
366
LT Debt
- -
- -
- -
55
108
53
47
- -
- -
9
Total Equity
117
275
303
338
576
603
636
700
798
864
Return on Invested Capital (%)
- -
- -
9.54
9.68
6.96
5.37
5.91
10.96
15.08
16
Return on Capital (%)
- -
- -
9.61
10.63
8.36
5.49
6.23
11.46
15.1
16.07
Return on Common Equity (%)
- -
-9.68
9.71
11.67
9.86
6.11
6.6
11.81
15.11
16.16

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
9
9
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
67
68
Market Capitalization
3,968
3,472
3,629

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
378
361
408
Cash, Cash Equivalents & STI
301
283
324
Accounts Receivable, Net
20
27
23
Inventories
45
43
48
Total Current Liabilities
35
38
43
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.92%
14.06%
Free Cash Flow
- -
19.58%
39.44%
Net Income, GAAP
- -
30.3%
43.47%
Sales/Revenue/Turnover
- -
24.56%
32.46%
Total Cash Common Dividend
- -
- -
46.3%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
57
65
69
88
278
2025
74
84
- -
120
369
2026
78
111
105
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.27
0.31
0.39
1.2
2025
0.37
0.35
- -
0.56
1.71
2026
0.31
0.54
0.5
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.39
- -
0.01
0.41
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jian Hua Wang
Full Time Employees
450
Sector
Health technology
Industry
Medical specialties
Address
Guangzhou China
IPO Date
Jul 26, 2021
Business
Medprin Regenerative Medical Technologies Co., Ltd. is a China-based medical device and regenerative medicine company engaged in the research, development, manufacturing, and commercialization of high-performance implantable biomaterials, surgical devices, and customized tissue repair solutions. Founded in 2008 and headquartered in Guangzhou, China, the company leverages precision biomaterial forming and biological 3D printing technologies to produce specialized medical products primarily focused on neurosurgery, craniomaxillofacial repair, wound management, and general surgery. The company operates through three primary business segments: Neurosurgical Implants and Biomaterials, Surgical Equipment and Consumables, and Advanced Wound Care and Regenerative Repair. Its core product portfolio comprises absorbable artificial dural repair patches marketed under the ReDura and NeoDura brand names for cerebral and spinal dural defect repair; patient-specific craniomaxillofacial bone repair systems, including three-dimensional printed polyetheretherketone (PEEK) cranial plates, customized bone meshes, and titanium fixation systems; bioabsorbable surgical hemostatic agents and flowable hemostatic matrices designed for intraoperative bleeding control; neurosurgical surgical power systems, including high-speed electric and pneumatic cranial drills, burs, and precision milling consumables; bioceramic bone graft substitutes and synthetic calcium phosphate bone repair matrices for orthopedic and cranial defect reconstruction; bioresorbable dural sealants and tissue adhesives for fluid-tight surgical closure; and medical-grade custom 3D anatomical modeling and digital surgical planning services. Medprin distributes its products domestically to tertiary hospitals across mainland China and exports internationally to healthcare institutions across Europe, Latin America, Southeast Asia, and the Middle East. In recent developments, Medprin Regenerative Medical Technologies has accelerated its product portfolio diversification and international commercial expansion. The company has secured expanded regulatory approvals, including National Medical Products Administration (NMPA) Class III registrations and international CE certifications, for its next-generation flowable absorbable hemostatic matrices and customized PEEK bone repair implants. Operationally, the company has expanded its manufacturing and R&D infrastructure in Guangzhou, enhancing automated production lines for biological 3D printing and electrospun nanofiber biomaterials to satisfy growing global clinical demand. Additionally, Medprin has scaled the commercial rollout of its proprietary neurosurgical power tool systems across hospital networks, deepened strategic distribution partnerships throughout Europe and the Asia-Pacific region, and broadened clinical research collaborations focused on regenerative biomaterials for spinal and soft-tissue reconstruction.